Protalix BioTherapeutics, Inc.
PLX · Biological Products, (No Diagnostic Substances) · 80.6M shares · +54%/yr ↑ shares · EDGAR filings ↗
Reference price $1.81 · est. market cap ~$146M — last insider purchase, 2025-12-19 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D48Biotherapeutics company (Elelyso/Fabry) with operating losses and cash burn.
Strengths
- Decent gross margin — 49%
- Adequate liquidity — current ratio 2.5 (33rd)
Risks
- Operating/net losses — operating margin -10%, net margin -13%
- Cash burn — FCF -$14M
- Partner/royalty dependence — per 10-K
Notable findings
- Net lossNet loss (net margin -12.5%)
- Cash burnNegative free cash flow (-13.6M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +54%/yr over 4y (dilution)
- Notable holderHeld by 5 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
48.8%
Operating margin
-10.4%
Net margin
-12.5%
Return on equity
-13.7%
Return on assets
-8.0%
Revenue growth (QoQ)
270.0%
Net-income growth
-325.2%
Current ratio
2.5×
Free cash flow
-$14M
Tangible book value
$48M
Cash & investments
$15M
Cash runway
4q
Stock comp / revenue
4.4%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-12-19 | Bashan Dror | Buy | 56K | $1.81 |
| 2025-11-18 | Bar-Shalev Amos | Sell | 168 | $1.87 |
| 2025-09-03 | Forster Eliot | Grant | 7.5K | — |
| 2025-09-03 | Elze Christian | Grant | 7.5K | — |
| 2025-09-03 | Melincoff Gwen A | Grant | 7.5K | — |
| 2025-09-03 | Boudes Pol F | Grant | 7.5K | — |
| 2025-09-03 | Schwartz Aharon | Grant | 7.5K | — |
| 2025-09-03 | Ben Zvi Shmuel | Grant | 7.5K | — |
| 2025-09-03 | Bar-Shalev Amos | Grant | 7.5K | — |
| 2025-09-03 | Naos Yaron | Grant | 25K | — |
| 2025-09-03 | Bashan Dror | Grant | 195K | — |
| 2025-06-10 | Schwartz Aharon | Buy | 129K | $1.60 |
All non-derivative Form 4 activity (SEC), newest first.
Supply chain
Customers (3)
- Chiesi Farmaceutici S.p.A.
- Fundação Oswaldo Cruz (Fiocruz)
- Pfizer Inc.
Suppliers (0)
Named in the 10-K; linked when we track them.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-25 | 2026-06-25 | 0001104659-26-077790 ↗ |
| 8-K | 2026-05-21 | 2026-05-21 | 0001104659-26-064850 ↗ |
| 8-K | 2026-05-13 | 2026-05-13 | 0001104659-26-059749 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001104659-26-059756 ↗ |
| 8-K | 2026-03-18 | 2026-03-18 | 0001104659-26-029846 ↗ |
| 10-K | 2026-03-18 | 2025-12-31 | 0001104659-26-029858 ↗ |
| 8-K | 2026-03-09 | 2026-03-09 | 0001104659-26-024975 ↗ |
| 8-K | 2026-02-11 | 2026-02-11 | 0001104659-26-013498 ↗ |
| 8-K | 2026-01-30 | 2026-01-30 | 0001104659-26-008410 ↗ |
| 8-K | 2026-01-05 | 2026-01-05 | 0001104659-26-000393 ↗ |
| 8-K | 2025-11-13 | 2025-11-13 | 0001104659-25-110821 ↗ |
| 10-Q | 2025-11-13 | 2025-09-30 | 0001104659-25-110824 ↗ |